Archive · 6 Aug 2025
AstraZeneca to Launch Eculizumab in India for Blood Disorders
AstraZeneca is bringing a new medicine called Eculizumab to India this August.
It's a special type of medicine that helps with rare and serious blood problems.
These problems, like PNH and aHUS, can damage blood cells and vessels, sometimes leading to kidney issues.
The medicine blocks a process that clogs tiny blood vessels.
The government approved this medicine earlier this year.
This medicine targets blood disorders.
This medicine is designed to make life better for people with these rare conditions.
AstraZeneca will launch Eculizumab, known as Soliris, in India this August.
The drug is for treating rare and severe blood disorders.
Regulatory clearance was received in January from CDSCO.
The approval allows the sale of Eculizumab concentrate for infusion 300 mg.
Soliris treats Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS).
- Who
- AstraZeneca.
- What
- AstraZeneca is launching Eculizumab (Soliris) in India.
- When
- August, after regulatory clearance in January.
- Where
- India.
- Why
- To treat rare blood disorders like PNH and aHUS.
- Drug Name
- Eculizumab (Soliris)
- Launch Date
- August
- Intended Use
- Treating rare blood disorders
- Approved for
- PNH and aHUS
- Approval Agency
- CDSCO
- Dosage Form
- Concentrate for infusion 300 mg